FDA grants approval for Veklury use in Covid-19 patients
This therapy is intended for use in patients with severe renal impairment including those on dialysis. The latest announcement comes after the decision from European Commission to extend
InterAx Biotech has entered a strategic research collaboration and licensing agreement with Alveus Therapeutics to develop a differentiated small-molecule therapeutic candidate for metabolic disease.